BeOne Medicines (BEIGF) Accounts Payables (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Accounts Payables data on file, last reported at $423.5 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $423.5 million, up 16.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $423.5 million (up 16.2% YoY), and the FY2025 annual result was $479.0 million, up 18.28% from the prior year.
• Accounts Payables eased to $423.5 million in Q1 2026 per BEIGF's latest filing, from $479.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $479.0 million in Q4 2025 and troughed at $234.4 million in Q2 2022.
• A 5-year average of $329.2 million and a median of $333.0 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables soared 61.25% in 2022, then dropped 10.04% in 2024.
• A 5-year view of Accounts Payables shows it stood at $294.8 million in 2022, then advanced by 6.9% to $315.1 million in 2023, then gained by 28.53% to $405.0 million in 2024, then advanced by 18.28% to $479.0 million in 2025, then retreated by 11.58% to $423.5 million in 2026.
• Business Quant data shows BEIGF's Accounts Payables at $423.5 million in Q1 2026, $479.0 million in Q4 2025, and $383.7 million in Q3 2025.